Purpose: DNA damage response and repair (DDR) gene alterations are associated with
increased tumor-infiltrating lymphocytes, higher genomic instability, and higher tumor�…

Immune checkpoint blockade with PD-(L) 1 antibodies has revolutionized the treatment of
advanced non-small cell lung cancer (NSCLC). Similarly, the identification and targeting of�…

Background Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a
subset of patients, consistent and easily obtainable predictors of efficacy remain elusive�…

Despite their key regulatory role and therapeutic potency, the molecular signatures of
interactions between T cells and antigen-presenting myeloid cells within the tumor�…

Despite advances made during the last two decades, lung cancer remains the leading
cause of cancer-related death worldwide. Recently, immune checkpoint inhibitors (ICIs)�…

Importance Immune checkpoint inhibitors (ICIs) can elicit durable antitumor responses in
patients with non–small cell lung cancer (NSCLC), but only 20% to 25% of patients respond�…

PD-1 immune checkpoint blockade occasionally results in durable clinical responses in
advanced metastatic cancers. However, mechanism-based predictors of response to this�…

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of�…

Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics.
Interestingly, elevated response rates to these agents are mostly documented among�…

Background Genetic variations of some driver genes in non-small cell lung cancer (NSCLC)
had shown potential impact on immune microenvironment and associated with response or�…